UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000061707 |
|---|---|
| Receipt number | R000070606 |
| Scientific Title | Elucidating the mechanisms of meniscal degeneration and extrusion in knee osteoarthritis using RNA sequencing |
| Date of disclosure of the study information | 2026/06/01 |
| Last modified on | 2026/05/27 16:43:12 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Elucidating the mechanisms of meniscal degeneration and extrusion in knee osteoarthritis using RNA sequencing
Acronym
Elucidating the mechanisms of meniscal degeneration and extrusion in knee osteoarthritis using RNA sequencing
Scientific Title
Elucidating the mechanisms of meniscal degeneration and extrusion in knee osteoarthritis using RNA sequencing
Scientific Title:Acronym
Elucidating the mechanisms of meniscal degeneration and extrusion in knee osteoarthritis using RNA sequencing
Region
| Japan |
Condition
Condition
knee osteoarthritis
Classification by specialty
| Orthopedics |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
In osteoarthritis of the knee, RNA-seq will be performed on meniscal tissue from groups with severe meniscal extrusion and groups with mild/no meniscal extrusion to clarify differences in cell subset composition, gene expression profiles, and signaling networks, thereby elucidating the molecular and cellular mechanisms of meniscal extrusion.
Basic objectives2
Others
Basic objectives -Others
In osteoarthritis of the knee, RNA-seq will be performed on meniscal tissue from groups with severe meniscal extrusion and groups with mild/no meniscal extrusion to clarify differences in cell subset composition, gene expression profiles, and signaling networks, thereby elucidating the molecular and cellular mechanisms of meniscal extrusion.
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Identification of differences in cell subset composition and gene expression profiles between the group with severe meniscal extrusion and the group with mild/no meniscal extrusion.
Key secondary outcomes
Base
Study type
Others,meta-analysis etc
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 60 | years-old | <= |
Age-upper limit
| 70 | years-old | > |
Gender
Female
Key inclusion criteria
Patients with osteoarthritis of the knee
Age 60 to under 70. Female.
Written informed consent obtained from the research participant.
Key exclusion criteria
Inflammatory joint diseases such as chronic rheumatoid arthritis and crystal-induced arthritis
History of infectious arthritis
Cases in which the same knee has undergone extensive meniscectomy or artificial joint replacement in the past
Cases where participation in the study is deemed inappropriate due to severe systemic complications
Target sample size
Research contact person
Name of lead principal investigator
| 1st name | Kuniaki |
| Middle name | |
| Last name | Ikeda |
Organization
Osaka Medical and Pharmaceutical University
Division name
Orthopedic surgery
Zip code
569-8686
Address
2-7, Daigakumachi, Takatsuki-shi, Osaka
TEL
072-683-1221
kei.tanaka@ompu.ac.jp
Public contact
Name of contact person
| 1st name | Kei |
| Middle name | |
| Last name | Tanaka |
Organization
Osaka Medical and Pharmaceutical University
Division name
Orthopedic surgery
Zip code
569-8686
Address
2-7, Daigakumachi, Takatsuki-shi, Osaka
TEL
080-6127-1030
Homepage URL
kei.tanaka@ompu.ac.jp
Sponsor or person
Institute
Osaka Medical and Pharmaceutical University
Institute
Department
Personal name
Funding Source
Organization
Osaka Medical and Pharmaceutical University
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Osaka Medical and Pharmaceutical University
Address
2-7, Daigakumachi, Takatsuki-shi, Osaka
Tel
072-683-1221
kei.tanaka@ompu.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 06 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2026 | Year | 05 | Month | 27 | Day |
Date of IRB
Anticipated trial start date
| 2026 | Year | 05 | Month | 27 | Day |
Last follow-up date
| 2030 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
before the start
Management information
Registered date
| 2026 | Year | 05 | Month | 27 | Day |
Last modified on
| 2026 | Year | 05 | Month | 27 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000070606
